1. Alpharetroviral Vector-Mediated Gene Therapy for IL7RA-Deficient Severe Combined Immunodeficiency.
- Author
-
Ha TC, Morgan MA, Thrasher AJ, and Schambach A
- Subjects
- Animals, Mice, Humans, Promoter Regions, Genetic, Mice, Knockout, T-Lymphocytes immunology, T-Lymphocytes metabolism, Interleukin-7 Receptor alpha Subunit genetics, Disease Models, Animal, Genetic Therapy methods, Genetic Vectors genetics, Genetic Vectors administration & dosage, Severe Combined Immunodeficiency therapy, Severe Combined Immunodeficiency genetics
- Abstract
Severe combined immunodeficiency (SCID) encompasses rare primary immunodeficiency disorders characterized by deficient T-cell development, which leads to a severely compromised immune system and susceptibility to life-threatening infections. Among SCID subtypes, IL7RA-SCID is caused by mutations in the interleukin 7 receptor alpha chain (IL7RA) and represents a significant subset of patients with limited treatment options. This study investigated the efficacy of a self-inactivating (SIN) alpharetroviral vector (ARV) engineered to deliver a codon-optimized IL7RA cDNA to restore T-cell development in Il7r -knockout mice. We compared the elongation factor 1 alpha short (EFS) promoter and the lymphoid-restricted Lck promoter for their ability to drive IL7RA expression and found that the EFS promoter enabled robust and sustained IL7RA expression that led to the functional rescue of T-lymphopoiesis in vitro and in vivo . Conversely, though effective in vitro , the Lck promoter failed to produce viable T-cell populations in vivo . Our results highlight the potential of using SIN-ARVs as a gene therapy (GT) strategy for treating IL7RA-SCID. Importantly, sustained production of T-lymphocytes was found in both primary and secondary transplant recipient animals with no adverse effects, supporting the safety and feasibility of this approach. Overall, this study provides valuable insights into the development of GT for IL7RA-SCID and underscores the clinical potential of an EFS-driven SIN-ARV to restore IL7RA-deficient immune function.
- Published
- 2024
- Full Text
- View/download PDF